Document is current
Any future updates will be listed below
-
Authors
Ruiz de Azua, Garazi
Licaj, Idlir https://orcid.org/0000-0003-3389-0735
Pinto, Sandrine
Havas, Julie
Di Meglio, Antonio
Vaz-Luis, Ines
Pistilli, Barbara https://orcid.org/0000-0002-9184-7199
André, Fabrice https://orcid.org/0000-0001-5795-8357
Martin, Anne-Laure
Everhard, Sibille
Jouannaud, Christelle
Fournier, Marion
Rouanet, Philippe
Dhaini-Merimeche, Asma
Sauterey, Baptiste https://orcid.org/0000-0001-9160-7307
Campone, Mario
Tarpin, Carole
Lerebours, Florence
Dumas, Agnès https://orcid.org/0000-0001-7948-6952
Menvielle, Gwenn https://orcid.org/0000-0002-3261-6366
-
Funding
Funding for this research was provided by:
Agence Nationale de la Recherche (n°ANR-10-COHO-0004)
Fondation ARC pour la Recherche sur le Cancer (PGA1 RF20170205420)
Institut National Du Cancer (SHS-E-SP 2022-138)
- License Information
-
More Information
Article History
Received: 2 July 2024
Revised: 22 August 2025
Accepted: 7 October 2025
First Online: 21 October 2025
Competing interests
: IVL: Honoraria: AstraZeneca (Inst), Amgen (Inst), Pfizer (Inst), Novartis (Inst), Sandoz (Inst); Research Funding: Resilience (Inst), Travel: Novartis. BP: Consulting fees: Astra Zeneca (institutional), Seagen (institutional), Gilead (institutional), Novartis (institutional), Lilly (institutional), MSD (institutional), Pierre Fabre (personal), Daiichi-Sankyo (institutional/personal); Research funding (to my institution): Astra Zeneca, Daiichi-Sankyo, Gilead, Seagen, MSD; Travel support: Astra Zeneca; Pierre Fabre; MSD; Daiichi-Sankyo; Pfizer.
: All methods were performed in accordance with the relevant guidelines and regulations.
: The study was approved by the national regulatory authorities and ethics committee (ID-RCB:2011-A01095-36, 312 11-039). CANcer TOxicities is a trial research involving the humans benefiting from authorization from the French National Agency for the Safety of Medicines and Health Products obtained on 14 September 2011 (number B111158-20) and from the Ile-de-France VII Committee for the Protection of Individuals obtained on 14 October 2011 (number 11-039). Informed consent was obtained from all subjects involved in the study.
: Not relevant. No individual person’s data.
